GlassScriptPhysician profile
Shagun Singh
NPI 1730634346
$886.80
in general payments reported to CMS, 2019-2025
19 companies · $887 in 2025
The $887 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $687 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $686.82 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $172.87 | 2025 | Zynyz, Monjuvi, Jakafi |
| Intuitive Surgical, INC. | $135.00 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $115.11 | 2025 | Lynparza |
| Janssen Biotech, INC. | $72.58 | 2025 | Darzalex, Tecvayli, Erleada |
| Pfizer INC. | $53.87 | 2025 | |
| Genzyme Corporation | $45.46 | 2025 | |
| Geron Corporation | $42.66 | 2025 | Rytelo |
| Takeda Pharmaceuticals U.S.A., INC. | $26.54 | 2025 | Livtencity |
| Daiichi Sankyo INC. | $25.50 | 2025 | Vanflyta |
| Novartis Pharmaceuticals Corporation | $23.86 | 2025 | |
| Deciphera Pharmaceuticals INC. | $23.26 | 2025 | Romvimza, Qinlock |
| Sobi, INC | $21.64 | 2025 | |
| Merck Sharp & Dohme LLC | $20.71 | 2025 | Welireg, Keytruda |
| Gilead Sciences, INC. | $20.59 | 2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $19.77 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $17.43 | 2025 | |
| Glaxosmithkline, LLC. | $17.34 | 2025 | Ojjaara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.86 | 2025 | |
| Aveo Pharmaceuticals, INC. | $15.75 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shagun Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.